SEATTLE SCIENCE FOUNDATION

INNOVATIVE APPROACHES TO BRAIN TUMOR MANAGEMENT

Friday, March 18, 2016
Seattle Science Foundation
550 17th Avenue
James Tower, Suite 600
Seattle, Washington 98122

JOINTLY PROVIDED BY

CONTINUING MEDICAL EDUCATION

SWEDISH
Extraordinary care. Extraordinary caring.

SEATTLE SCIENCE FOUNDATION
COURSE DESCRIPTION

The Innovative Approaches to Brain Tumor Management Course is targeted towards healthcare providers who manage and treat patients with brain tumors. Leading experts in the field will come together to discuss the future of brain tumor management including the progress in personalized medicine and implications of immunotherapy in specializing treatment. The design is to focus on the future of brain tumor therapy with the goal of improving treatment response rates, outcomes, and overall patient care.

NEEDS STATEMENT

This course provides a targeted focus on brain tumors covering the future of brain tumor management and treatment including the application of personalized medicine and immunotherapy.

OBJECTIVES

By attending this course, the participant will provide better patient care through an increased ability to:

• Apply new knowledge of personalized medicine and immunotherapy in brain tumor management to their clinical practice.
• Explain the benefits and obstacles of personalized medicine and immunotherapy treatment.
• Integrate the knowledge of targeting tumor markers, use of vaccines and antiviral therapy and tracking biomarkers into their practice.
• Utilize the mechanism of action behind an engineered virus delivered via vaccine.
• Discuss current treatment options for malignant meningioma with their patients.

ACKNOWLEDGMENTS

This symposium is financially supported in part by educational grants in accordance with ACCME’s Standards for Commercial Support. At the time of this printing, a complete listing of commercial supporters was not available. Appropriate acknowledgment will be given to all supporters at the time of the symposium.

INTENDED AUDIENCE

The sessions are targeted to neurosurgeons, neuro-oncologists, medical oncologists, neuroradiologists, radiation therapists, and allied health professionals who specialize in the treatment of patients with brain tumors.

CME INFORMATION

Accreditation with Commendation
Swedish Medical Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA PRA Category 1 Credits™
Swedish Medical Center designates this live activity for a maximum of 6.75 AMA PRA Category 1 credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Contact Hours
Nursing contact hours will be provided by Swedish Medical Center Clinical Education and Practice, an approved provider of continuing nursing education by the Washington State Nurses Association Continuing Education Approval & Recognition Program (CEARP), an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.

PLANNING COMMITTEE

Charles Cobbs, M.D., Course Chair
Caye Boosalis, CME Manager
Clara Greaney
Jeni Page, ACNP-BC
Davida Pennington
Elaina Robinson, R.N., Clinical Educator
Linda Sahlin

LOCATION

The Seattle Science Foundation is located at 550 17th Avenue, James Tower, Suite 600 in Seattle, Washington. Parking is available in the garage on 16th Avenue between Cherry and Jefferson at a maximum fee of $16.50. From I-5 (northbound and southbound), take the James Street exit. Travel east on James Street. James will become Cherry Street. Turn right (south) on 16th Avenue. Turn right into the main garage entrance.

FOR FURTHER INFORMATION

Phone: (206) 732-6500
Fax: (206) 732-6599
E-mail: info@seattlesciencefoundation.org
Web: www.seattlesciencefoundation.org
FEATURED FACULTY

Nitin Baliga, Ph.D.
Senior Vice President and Director,
Institute for Systems Biology
Seattle, Washington

Mitchell Berger, M.D.
Professor and Chairman, Department of Neurological Surgery
University of California San Francisco
San Francisco, California

Marc C. Chamberlain, M.D.
Professor, Neurology and Neurological Surgery
University of Washington School of Medicine
Seattle Cancer Care Alliance
Seattle, Washington

Charles Cobbs, M.D.,
Course Chair
Medical Director, Ben and Catherine Ivy Center for Advanced Brain Tumor Treatment
Swedish Neuroscience Institute
Seattle, Washington

Eric Holland, M.D., Ph.D.
Senior Vice President and Director
Fred Hutchinson Cancer Research Center
Seattle, Washington

Leroy Hood, M.D., Ph.D.
President and Co-founder
Institute for Systems Biology
Seattle, Washington

Gregory Foltz, M.D., Visiting Professor - Honored Guest

Parvinder Hothi, Ph.D.
Senior Scientist
Ben and Catherine Ivy Center for Advanced Brain Tumor Treatment
Swedish Neuroscience Institute
Seattle, Washington

Linda Liau, M.D.
Professor and Director,
UCLA Brain Tumor Program
Ronald Reagan UCLA Medical Center
Los Angeles, California

Michael Prados, M.D.
Professor in Residence, Neurological Surgery, Charles B. Wilson MD Endowed Chair
University of California, San Francisco
San Francisco, California

Cecilia Söderberg Nauclér, M.D., Ph.D.
Professor, Karolinska Institutet
Stockholm, Sweden
7:30 a.m.  Breakfast & Registration
8:00 a.m.  Welcome & Announcements  Charles Cobbs, M.D.
8:15 a.m.  Keynote Address: The Future of Personalized Cancer Medicine  Leroy Hood, M.D., Ph.D., Honored Guest
   • Discuss the future treatment options, surgical and non-surgical, for brain tumors.
   • Identify characteristics of personalized medicine.
   • Review advantages and disadvantages of personalized medicine in the treatment of brain tumors.
9 a.m.  The Evolution of Classifying Brain Tumors: All Tumors are Different  Eric Holland, M.D., Ph.D.
   • Review history of classification system.
   • Review current classification systems for brain tumors.
   • Discuss areas of continued debate with tumor classification.
9:30 a.m.  Clinical Trials with Cancer Stem Cells: The Future of Treatment  Nitin Baliga, Ph.D. & Parvinder Hothi, Ph.D.
   • Review current clinical trial description.
   • Describe methods of treatment.
   • Discuss benefits and obstacles currently encountered in clinical trials.
10 a.m.  Panel Discussion
   • Review history of brain tumor treatment.
   • Discuss the future of therapy.
   • Discuss obstacles in current research and clinical trials.
10:30 a.m.  Break
10:45 a.m.  Personalized Approach to GBM Therapy  Michael Prados, M.D.
   • Describe the use of tumor markers for treatment in brain cancer.
   • Review the mechanism of action with targeting tumor markers.
   • Describe the benefits to treatment.
11:15 a.m.  The Future of Vaccine Treatment in Brain Cancer: Personalized Immunotherapy  Linda Liau, M.D.
   • Describe vaccine treatment in brain cancer.
   • Discuss the benefits of personalized immunotherapy.
   • Discuss the obstacles encountered with personalized immunotherapy.
11:45 a.m.  Panel Discussion
   • Identify the benefits of personalized medicine in brain tumor treatment.
   • Review mechanisms behind personalized medicine.
   • Discuss future direction with personalized medicine in brain tumor treatment.

Lunch & Tour of the Ivy Center

Overview of WHO Grade 2 and 3 Gliomas  Marc C. Chamberlain, M.D.
   • Review current epidemiology and molecular biology of intermediate grade gliomas.
   • Summarize current treatment strategies of intermediate grade gliomas.

Innovative Surgical Techniques in Brain Tumor Surgery  Mitchell Berger, M.D.
   • Discuss the benefits of intraoperative brain mapping in tumor resection.
   • Review standard of care surgical techniques for brain tumor resections.
   • Identify risk of brain tumor surgery and discuss avoidance techniques.

Panel Discussion

Treating Viral Activity in Brain Tumors: The Future with Antivirals  Cecilia Söderberg-Nauclér, M.D., Ph.D.
   • Discuss the viral activity identified in brain tumors.
   • Review the mechanism of action behind antiviral therapy.
   • Discuss the benefits of antiviral therapy.

Break & Exhibits

Brain Tumor Biomarkers: Latest Research in Specializing Treatments  Charles Cobbs, M.D. & Leroy Hood, M.D., Ph.D.
   • Discuss biomarkers and how they change with tumor progression and treatment.
   • Review benefits of tracking biomarkers.
   • Identify future goals with tracking brain tumor biomarkers for specializing therapy.

Panel Discussion

• Identify broader spectrum of potential with vaccine therapy in brain tumor treatment.
• Review obstacles in the treatment of challenging and aggressive brain tumors.
• Discuss future goals in the field of brain tumor therapy.

Adjourn
COMMUNITY EDUCATION

INNOVATIVE APPROACHES TO BRAIN TUMOR MANAGEMENT

5:30 - 8 p.m.
Seattle Science Foundation

This course is targeted towards people with brain tumors, their families and friends.

5:30 p.m.  Patient Registration
            Appetizers Served.

6 p.m.  Welcome & Introduction
        Charles Cobbs, M.D.

6:05 p.m.  Panel Discussion: Innovative Approaches to Brain Tumor Management

7 p.m.  Breakout Sessions
• Clinical Trials with Cancer Stem Cells
• Brain Tumor Biomarkers
• The Future of Vaccine Treatment in Brain Cancer
• Personalized Approach to GBM

8 p.m.  Adjourn
Dr. Hood's outstanding contributions have had a resounding effect on the advancement of science since the 1960s. Throughout his career, he has adhered to the advice of his mentor, Dr. William J. Dreyer: “If you want to practice biology, do it on the leading edge, and if you want to be on the leading edge, invent new tools for deciphering biological information.”

Hood was involved in the development of five instruments critical for contemporary biology—namely, automated DNA sequencers, DNA synthesizers, protein sequencers, peptide synthesizers, and an ink jet printer for constructing DNA arrays. These instruments opened the door to high-throughput biological data and the era of big data in biology and medicine. He helped pioneer the human genome program—making it possible with the automated DNA sequencer. Under Hood's direction, the Human Genome Center sequenced portions of human chromosomes 14 and 15.

In 1992, Hood created the first cross-disciplinary biology department, Molecular Biotechnology, at the University of Washington. In 2000, he left the UW to co-found Institute for Systems Biology, the first of its kind. He has pioneered systems medicine the years since ISB's founding. Hood has made many seminal discoveries in the fields of immunology, neurobiology and biotechnology and, most recently, has been a leader in the development of systems biology, its applications to cancer, neurodegenerative disease, and the linkage of systems biology to personalized medicine.

Hood is now pioneering new approaches to P4 medicine—predictive, preventive, personalized and participatory, and most recently, has embarked on creating a P4 pilot project on 100,000 well individuals, that is transforming healthcare.

In addition to his ground-breaking research, Hood has published 750 papers, received 36 patents, 17 honorary degrees and more than 100 awards and honors. He is one of only 15 individuals elected to all three National Academies—the National Academy of Science, the National Academy of Engineering, and the Institute of Medicine. Hood has founded or co-founded 15 different biotechnology companies including Amgen, Applied Biosystems, Rosetta, Darwin, Integrated Diagnostics, Indi Molecular and Arivale.
HONORING THE LEGACY OF GREGORY FOLTZ, M.D.

The lectureship was created to bring likeminded colleagues together to share the latest updates in personalized medicine and to help find a cure for patients with terminal brain cancer.
REGISTRATION FORM

REGISTRATION INFORMATION:
Pre-registration is required as space is limited. The discounted “Advance Registration” deadline is March 7, 2016. Registrations will only be processed and confirmed when accompanied by full payment.

If using the registration form, please mail or fax it to:
Seattle Science Foundation
550 17th Avenue, James Tower, Suite 600
Seattle, WA 98122
Fax: (206) 732-6599

Cancellation: To receive a refund, notice of cancellation must be received no later than March 14, 2016.

If you have special needs, please contact us at (206) 732-6500.

REGISTER ONLINE
www.seattlesciencefoundation.org

INNOVATIVE APPROACHES TO BRAIN TUMOR MANAGEMENT
March 18, 2016

NAME

TITLE/CREDENTIALS

ADDRESS

CITY/STATE/ZIP

PHONE

FAX

EMAIL

SPECIALTY

Registration Fees

Advanced Registration

After March 7, 2016

M.D. or D.O. ___ $300 ___ $330
Allied Health Professionals ___ $275 ___ $305
Medical Student ___ $50 ___ $50
Resident/Fellow ___ $50 ___ $50

Check enclosed, payable to Seattle Science Foundation.

Credit Card # _____________________________________________________________

Visa ___ MasterCard ___ Discover ___ AMEX

Signature ____________________________________________ Expiration Date __________

Seattle Science Foundation
550 17th Avenue, James Tower, Suite 600
Seattle, WA 98122